Arvinas (ARVN)
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing prot...
- Open
- 8.990
- High
- 9.115
- Low
- 8.860
- Prev. Close
- 8.990
- Volume
- 572.10K
- Turnover
- 5.13M
- Avg Price
- 8.960
- Bid/Ask Ratio
- -98.20%
- Amplitude
- 2.84%
- 52wk High
- 14.510
- Volume Ratio
- 0.74
- Turnover Ratio
- 1.04%
Arvinas Analyst Rating
View moreForecast & Rating
Aug 10, 2026Price forecast
$13.9354.93%
Forecast & RatingBuy
16analysts
- Strong buy31.25%
- Buy12.50%
- Hold50.00%
- Sell6.25%
- Strong sell0.00%
News
- PUBT · Aug 7 at 07:04 AM
Arvinas posts corporate presentation highlighting PROTAC degrader pipeline in oncology and neurology
- Market Beat · Aug 5 at 09:40 AM
Arvinas (NASDAQ:ARVN) Trading Down 7.8% on Analyst Downgrade
- TradingKey · Aug 5 at 02:02 AM
Arvinas Q2 2026 earnings: Licensing revenue drives a return to profit
- PUBT · Aug 4 at 05:33 PM
Rigel Pharmaceuticals posts corporate deck highlighting VEPPANU in-license and commercial launch plan
- Market Beat · Aug 4 at 01:06 PM
Arvinas' (ARVN) "Equal Weight" Rating Reaffirmed at Wells Fargo & Company
- Quartr · Aug 4 at 06:21 AM
ARVN: First FDA-approved PROTAC and out-licensing drove record Q2 revenue and net income
